Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Allena Pharmaceuticals Inc    ALNA

ALLENA PHARMACEUTICALS INC

(ALNA)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/10/2019 07/11/2019 07/12/2019 07/15/2019 07/16/2019 Date
5.16(c) 5.08(c) 4.94(c) 4.97(c) 4.9(c) Last
169 881 320 626 114 117 41 000 40 188 Volume
+5.31% -1.55% -2.76% +0.61% -1.41% Change
More quotes
Financials (USD)
Sales 2019 -
EBIT 2019 -47,4 M
Net income 2019 -47,0 M
Finance 2019 12,2 M
Yield 2019 -
Sales 2020 -
EBIT 2020 -54,2 M
Net income 2020 -54,0 M
Finance 2020 66,3 M
Yield 2020 -
P/E ratio 2019 -2,36x
P/E ratio 2020 -2,40x
EV / Sales2019 infx
EV / Sales2020 infx
Capitalization 115 M
More Financials
Company
Allena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177,... 
More about the company
Surperformance© ratings of Allena Pharmaceuticals Inc
Trading Rating : Investor Rating : -
More Ratings
Latest news on ALLENA PHARMACEUTICALS INC
06/28ALLENA PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Finan..
AQ
06/27Allena Pharmaceuticals Announces $10.0 Million Registered Direct Offering of ..
GL
06/24ALLENA PHARMACEUTICALS : Showcases Reloxaliase and Enteric Hyperoxaluria Program..
AQ
06/22ALLENA PHARMACEUTICALS : Showcases Reloxaliase and Enteric Hyperoxaluria Program..
AQ
06/21ALLENA PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (..
AQ
06/21Allena Pharmaceuticals Showcases Reloxaliase and Enteric Hyperoxaluria Progra..
GL
06/07ALLENA PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holde..
AQ
06/04ALLENA PHARMACEUTICALS, INC. : Regulation FD Disclosure, Other Events, Financial..
AQ
06/04Allena Pharmaceuticals Announces Interim Results from Study 206 of Reloxalias..
GL
05/30Allena Pharmaceuticals to Present at Jefferies 2019 Healthcare Conference
GL
More news
Sector news : Bio Therapeutic Drugs
08:36pAs steep patent cliff looms, Shionogi moves to develop its own U.S. sales sta..
RE
12:40pGSK's two-drug HIV Dovato treatment meets main goal in study
RE
07/15Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
07/15Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
07/15GLOBAL MARKETS LIVE : Facebook, Gilead, AB Inbev, Boeing…
More sector news : Bio Therapeutic Drugs
Chart ALLENA PHARMACEUTICALS INC
Duration : Period :
Allena Pharmaceuticals Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALLENA PHARMACEUTICALS INC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 30,00  $
Last Close Price 4,90  $
Spread / Highest target 1 145%
Spread / Average Target 512%
Spread / Lowest Target 308%
EPS Revisions
Managers
NameTitle
Louis Brenner Chief Executive Officer & Director
Alexey L. Margolin Chairman
Edward Wholihan CFO, Principal Accounting Officer & VP-Finance
Hugh Wight Vice President-Technical Operations
Robert Ira Tepper Director
Sector and Competitors
1st jan.Capitalization (M$)
ALLENA PHARMACEUTICALS INC-10.09%119
GILEAD SCIENCES8.82%84 164
VERTEX PHARMACEUTICALS6.43%45 080
REGENERON PHARMACEUTICALS-20.16%31 857
SAREPTA THERAPEUTICS INC43.78%11 437
GENMAB11.33%11 148